Ada Braun
Amgen (United States) · 81 works · 4,444 citations · h-index 22
Top works
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
- Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
- Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor
- Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
- Denosumab for Treatment of Hypercalcemia of Malignancy
- Hypocalcaemia in patients with metastatic bone disease treated with denosumab
- Pain outcomes in patients with advanced breast cancer and bone metastases
- Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid
- 2LBA Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study
- Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
- Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study
- New systemic frontline treatment for metastatic colorectal carcinoma
- Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics
- Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid
- The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease
- Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases
- Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone
- Assessing Analgesic Use in Patients with Advanced Cancer: Development of a New Scale-The Analgesic Quantification Algorithm
- Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial
- The development of denosumab for the treatment of diseases of bone loss and cancer‐induced bone destruction